BetterLife Pharma (BETRF) Receivables (2014 - 2026)

BetterLife Pharma has reported Receivables for 11 years, with the latest figure at $5817.1 in Q2 2026.

• On a quarterly basis, Receivables rose 0.92% year-over-year to $5817.1 in Q2 2026; TTM through Apr 2026 was $5817.1, a 0.92% increase from a year earlier, with the FY2026 full-year figure at $2051.3, down 75.74% from the prior year.
• Receivables was $5817.1 for Q2 2026 at BetterLife Pharma, up from $2057.9 in the prior quarter.
• The five-year high for Receivables was $256771.0 in Q1 2022, with the low at $2057.9 in Q1 2026.
• Average Receivables over 5 years is $27587.4, with a median of $12749.0 recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Receivables slumped 95.03% in 2023, then jumped 129.4% in 2024.
• Over 5 years, Receivables stood at $24052.0 in 2022, then sank by 60.68% to $9457.6 in 2023, then sank by 43.14% to $5377.9 in 2024, then increased by 24.47% to $6694.2 in 2025, then fell by 13.1% to $5817.1 in 2026.
• The last three Receivables figures came in at $5817.1 (Q2 2026), $2057.9 (Q1 2026), and $6694.2 (Q3 2025), per Business Quant data.